Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 2.95
-2.64 %
$ 8.87 M
Market Cap
-0.03
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart BNGO
FINANCIALS
Balance Sheet
Bionano Genomics, Inc.
| Current Assets | 39.5 M |
| Cash & Short-Term Investments | 9.48 M |
| Receivables | 4.77 M |
| Other Current Assets | 25.2 M |
| Non-Current Assets | 37.2 M |
| Long-Term Investments | 0 |
| PP&E | 24.3 M |
| Other Non-Current Assets | 12.9 M |
| Current Liabilities | 37.3 M |
| Accounts Payable | 6.96 M |
| Short-Term Debt | 23.6 M |
| Other Current Liabilities | 6.77 M |
| Non-Current Liabilities | 3.95 M |
| Long-Term Debt | 3.68 M |
| Other Non-Current Liabilities | 267 K |
EFFICIENCY
Earnings Waterfall
Bionano Genomics, Inc.
| Revenue | 30.8 M |
| Cost Of Revenue | 30.4 M |
| Gross Profit | 380 K |
| Operating Expenses | 104 M |
| Operating Income | -104 M |
| Other Expenses | 8.03 M |
| Net Income | -112 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Bionano Genomics, Inc.
| Net Income | -112 M |
| Depreciation & Amortization | 14.2 M |
| Capital Expenditures | -103 K |
| Stock-Based Compensation | 9.74 M |
| Change in Working Capital | 0 |
| Others | 19.1 M |
| Free Cash Flow | -69 M |
Wall Street Analysts Price Targets
Bionano Genomics, Inc.
Wall Street analysts predict an average 1-year price target for BNGO of $1.88 , with forecasts ranging from
a
low of
$1 to a high of $3.5 .
BNGO Lowest Price Target
Wall Street Target
1 USD
-66.10%
BNGO Average Price Target
Wall Street Target
1.88 USD
-36.44%
BNGO Highest Price Target
Wall Street Target
3.5 USD
18.64%
4. DIVIDEND
ANALYSIS
BNGO does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Bionano Genomics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Bionano Genomics, Inc. (BNGO) Q4 2024 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Operator Good day, and welcome to the Bionano Fourth Quarter 2024 Earnings Conference Call. Today's conference is being recorded.
seekingalpha.com
- 1 week ago
Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook for 2025. “2024 has been an important year for Bionano.
globenewswire.com
- 1 week ago
Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect
SAN DIEGO, and GREENWOOD, S.C., March 24, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) and Greenwood Genetic Center (GGC) today announced a publication in Genome Research describing the first study to use optical genome mapping (OGM) to investigate the genetic landscape of neural tube defects (NTDs). NTDs are the most common birth defect of the central nervous system and some of the most devastating congenital conditions. Despite an expected genetic link in as many as 60-70% of cases, methods currently in use, including karyotyping (KT), chromosomal microarray (CMA) and next-generation sequencing (NGS), collectively identify pathogenic gene variants in only about 8% of cases, suggesting more work is needed to better understand the underlying genetic drivers of NTDs.
globenewswire.com
- 2 weeks ago
Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) 2025 Annual Meeting
Featured Scientific Session: "Evolution of Cytogenomic Technology: Real-World Applications of Optical Genome Mapping in the Laboratory", an accredited continuing medical education (CME) session, with a panel of experts presenting research on OGM's clinical and translational applications. Dr. Adam Smith (University of Toronto, Canada; currently at Labcorp, USA) will provide an overview of OGM's evolution into an essential tool for hematological malignancy research and its role in research of pre- and post-natal constitutional genetic disease.
globenewswire.com
- 3 weeks ago
Bionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025
SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 31, 2025, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2024 and to highlight recent corporate progress.
globenewswire.com
- 3 weeks ago
Bionano Announces Publication Reporting First Use of OGM to Detect Chromoanagenesis, a Key Marker of Poor Prognosis in AML
In-Motion Webinar: Bionano will host a webinar featuring the study's lead author, Dr. Guilin Tang, who will discuss the study and its findings in detail, including a summary of the potential implications for wide-spread adoption of optical genome mapping Time and Date: April 15, 2025 at 9:30 AM Central Time, USA Registration details to be made available at Bionano.com SAN DIEGO, March 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in the American Journal of Hematology demonstrating the potential utility of optical genome mapping (OGM) for detecting structural variants associated with chromoanagenesis (CAG) in acute myeloid leukemia (AML). CAG is a catastrophic genomic event that is frequently associated with highly complex karyotypes, extensive clonal heterogeneity, treatment resistance, and poor prognosis compared to subjects with no detectable CAG.
globenewswire.com
- 4 weeks ago
Bionano Announces Effective Date of Reverse Stock Split
SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO)(the “Company”) today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-60. The effective time of the reverse stock split will be 5 p.m.
globenewswire.com
- 2 months ago
Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of common stock (or per common stock equivalent) and accompanying Warrant. The Warrants have an exercise price of $0.252 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”).
globenewswire.com
- 3 months ago
Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of common stock (or per common stock equivalent) and accompanying Warrant in a registered direct offering priced at-the-market under Nasdaq rules. The Warrants will have an exercise price of $0.252 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”) for a period of five years thereafter.
globenewswire.com
- 3 months ago
Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
SAN DIEGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a settlement agreement and amendment to its outstanding senior secured convertible debentures due May 26, 2024 (the “Amendment”). Importantly the Amendment defers the Company's December 2024 amortization payment and reduces the payments due in January 2025 through July 2025 from $1,000,000 per month to $500,000 per month.
globenewswire.com
- 3 months ago
Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis
SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Modern Pathology by a group of researchers at the Johns Hopkins University School of Medicine, showing that optical genome mapping (OGM) can outperform traditional techniques in analysis of bone and soft tissue tumors. Several prior publications have shown the utility of OGM compared to traditional cytogenetics in studies of hematologic malignancies, however, data on the application of OGM in solid tumors has been relatively sparse. This study provides compelling support for extending the utility of OGM in cancer beyond hematologic malignancies to solid tumors.
globenewswire.com
- 3 months ago
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Destiny Hance - Ladenburg Thalmann Mark Massaro - BTIG Operator Good day, and welcome to the Bionano Third Quarter 2024 Earnings Conference Call. Today's conference is being recorded.
seekingalpha.com
- 4 months ago
8. Profile
Summary
Bionano Genomics, Inc. BNGO
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 8.87 M
Dividend Yield
0.00%
Description
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Contact
9540 Towne Centre Drive, San Diego, CA, 92121
https://www.bionanogenomics.com
IPO
Date
Aug. 21, 2018
Employees
344
Officers
Mr. Stanislas Marin M.B.A., M.S.
Vice President of Global Sales
Mr. Cory Kreeck
Global Head of People Operations
Dr. Robert Erik Holmlin M.B.A., Ph.D.
President, Chief Executive Officer & Director and Chief Financial Officer
Mr. Mark Adamchak CPA
Vice President of Accounting & Controller
Mr. Jonathan Dixon J.D.
General Counsel & Secretary
Ms. Donna Polizio
Global Head of Market Access
Mr. Mark Oldakowski
Chief Operating Officer
Dr. Alka Chaubey FACMG, Ph.D.
Chief Medical Officer